Retatrutide: The Trial Behind 28% Weight Loss

In TRIUMPH-1, the highest-dose retatrutide group lost an average of 28.3% of body weight over 80 weeks under the trial's efficacy analysis. Nearly half reached at least 30% weight loss. Those are results in the range often discussed with bariatric surgery, from one molecule that activates three hormone receptors.

The Phase 3 trial enrolled 2,339 adults without diabetes. Their average starting weight was 112.7 kg, about 248 pounds, and their average BMI was 40. Researchers compared three retatrutide doses with placebo in a double-blind trial.

The TRIUMPH-1 paper was published in NEJM on September 29, 2026. Its primary weight analysis reports 25.0% for the highest dose. Understanding why the same trial produces both numbers also explains why tolerability deserves as much attention as the headline.

A receptor is a protein that receives a chemical signal and starts a response in a cell. A drug that activates it is called an agonist. Retatrutide activates the receptors for GLP-1, GIP and glucagon, which help the body handle nutrients and energy.

Researchers built the 39-amino-acid molecule using a GIP peptide as the starting structure. They also attached a fatty-acid component that binds to albumin, a protein in blood, to keep the drug in circulation longer.

The glucagon target has a specific experimental rationale. In obese mice, retatrutide maintained energy expenditure while animals eating the same reduced amount of food used less energy. Blocking the glucagon receptor removed that energy-expenditure effect while leaving the reduction in food intake intact.

That experiment helps explain why researchers built the molecule this way. It does not tell us how many extra calories a person will burn each day. The discovery paper called for further human studies of that mechanism. Coskun et al., Cell Metabolism, 2022

Counting receptors alone cannot settle which treatment is best. An additional target creates another biological effect to test. The useful question is what the whole molecule does in people, at doses they can tolerate.

In the 2023 Phase 2 trial published in the New England Journal of Medicine, researchers randomized 338 adults without diabetes to different retatrutide regimens or placebo. Participants had obesity, or overweight with a weight-related condition. All groups received diet and physical-activity counseling.

The 12 mg group had an estimated average weight reduction of 17.5% at 24 weeks and 24.2% at 48 weeks. Placebo produced 1.6% and 2.1%, respectively. These were modeled results for the trial's efficacy analysis.

The longer observation showed that the weight-loss effect continued beyond the first several months. It also exposed practical problems. Gastrointestinal events were common, especially during dose increases. Heart rate rose, peaked at 24 weeks and then declined. Across the trial, 78% completed the assigned treatment period.

This was the study behind the earlier 24% headline. The next step was to test the drug in a much larger population for longer. Jastreboff et al., NEJM, 2023

An estimand is the treatment effect a trial is designed to estimate. It defines, among other things, how the analysis handles a participant stopping treatment.

The efficacy estimand asks what would happen if participants remained on study treatment without starting prohibited weight-management therapies. The treatment-regimen estimand includes outcomes regardless of adherence. NEJM uses the latter for its primary weight results.

Here is the average weight loss at 80 weeks. The doses identify the trial groups.

Sources: NEJM, September 2026 and Lilly's TRIUMPH-1 results.

The treatment-regimen result gives a fuller account of what happened when treatment interruptions and discontinuations were part of the experience. The 25.0% figure is still a trial average. It cannot predict one person's result.

The 4 mg group reached its target dose after one escalation step and lost 19.0% under the efficacy analysis. That is a substantial result from the lowest target dose tested in this trial.

The gap between 9 mg and 12 mg was 2.4 percentage points in that analysis. Under the treatment-regimen analysis, it was 1.3 points. The higher dose added weight loss, but the size of that gain needs to sit beside the reasons people stopped treatment.

These reported discontinuation rates make the dose question concrete. The highest-dose group had more people stop because of side effects. The trial does not establish a universal best dose or a prescribing plan.

In the 12 mg group, 45.3% reached at least 30% weight loss under the efficacy analysis. Another threshold helps show the depth of the response: 27.2% reached at least 35% weight loss.

Lilly also reported that 65.3% of the 12 mg group reached a BMI below 30. Among those who started with a BMI of at least 40, 37.5% crossed below 30. The latter was a post-hoc analysis, meaning it was conducted after the original analysis plan.

These results make the surgery comparison understandable. TRIUMPH-1 compared retatrutide with placebo, so it cannot establish that the drug matches surgery's long-term benefits or risks. TRIUMPH-1 results and analysis notes

The 104-week extension adds another result: 30.3% average weight loss in the group originally assigned to 12 mg, under the efficacy analysis. That extension involved 532 selected participants with a starting BMI of at least 35 who completed and tolerated the main study. Extension treatment targeted a maximum tolerated dose of 9 or 12 mg. Its result describes that selected group.

Gastrointestinal symptoms were common. Lilly reported nausea in 28.6%, 38.4%, and 42.4% of the 4, 9, and 12 mg groups, respectively, versus 14.8% with placebo. Vomiting affected 10.6%, 22.8%, and 25.3%, versus 4.8%.

There was also dysesthesia, an unpleasant or altered sensation that can feel like burning or tingling. TRIUMPH-1 rates were 5.1%, 12.3%, and 12.5%, versus 0.9% with placebo. These are the rates from this trial. Lilly reported that these events were generally mild to moderate and that most resolved during treatment. Safety results

At the June 2026 American Diabetes Association meeting, lead investigator Ania Jastreboff reported serious adverse events in 7.7% to 10.5% across retatrutide groups, versus 5.5% with placebo. An event occurring during a trial does not by itself establish that the medicine caused it. Gastrointestinal events were the most common reason for stopping because of an adverse event. Investigator presentation

For future care, the important question is how much benefit someone can sustain while remaining well enough to continue treatment. A higher target dose adds another tradeoff to that decision.

The September NEJM report includes 574 participants with knee osteoarthritis and 243 with obstructive sleep apnea. These groups let researchers measure consequences of obesity that people feel each day.

Researchers measured knee pain with a standardized questionnaire in which lower scores mean less pain. In the intention-to-treat analysis, which includes participants regardless of treatment adherence, scores fell by 4.1 points in the 12 mg group and 2.5 points with placebo. Among participants with sleep apnea, the same type of analysis found 32.1 fewer breathing pauses or reductions per hour with 12 mg, versus 9.6 fewer with placebo. NEJM abstract

The investigator presentation also reported improvements in blood pressure, blood lipids, inflammation measured by hsCRP, and blood glucose. Those measurements help explain the interest in retatrutide beyond weight loss. Cardiovascular events still need their own outcome evidence. ADA presentation

A separate analysis of the Phase 2 trial examined 98 participants whose liver fat content was at least 10% on MRI. At 24 weeks, the 12 mg group had an estimated 82.4% relative reduction in liver fat, while placebo showed a 0.3% increase.

This measures change in the liver's fat fraction. It is different from the percentage of body weight lost on a scale. For a simple illustration, reducing a fat fraction from 20% to 4% is an 80% relative reduction, or a 16-percentage-point drop. That example is arithmetic, not a participant's result.

The investigators had 24-week MRI data for 77 of the 98 participants. They did not take liver biopsies. The findings support a large effect on liver fat in this selected group; they do not establish that retatrutide reverses advanced liver scarring or prevents liver failure. Sanyal et al., Nature Medicine, 2024

A scale cannot show where a person's fat is changing. The MRI study adds a measurement that matters to readers with fatty liver disease. It also gives them a more precise question to bring to a clinician: which aspect of their liver condition needs treatment, and how will improvement be measured?

In July 2026, Lilly reported results from two more Phase 3 trials. In TRIUMPH-2, involving adults with type 2 diabetes and obesity or overweight, the 12 mg group lost an estimated 20.8% at 80 weeks versus 4.0% with placebo. In TRIUMPH-3, participants had severe obesity and established cardiovascular disease; the corresponding figures were 22.6% and 3.2%. Both comparisons used efficacy analyses.

The cardiovascular findings also need their own reading. TRIUMPH-3's analyses of major cardiovascular events did not establish a reduction: the confidence intervals included the possibility of no difference between treatments. Its weight-loss result cannot substitute for evidence of fewer heart attacks or strokes. Lilly's July report

These were separate trials in different populations. The difference between their averages cannot tell us what caused a particular person to respond more or less. It does show why a treatment comparison needs to name the people studied.

A direct comparison with another weight-loss drug, tirzepatide, is underway in TRIUMPH-5. Lilly's trial record lists completed enrollment and a planned end in December 2026. As of October 1, 2026, results had not been reported. TRIUMPH-5

If you are already receiving obesity care, bring the specific outcome you want to improve to your next visit. Your clinician can then compare available treatments using your medical history and what has happened with treatment so far. Ask how benefit will be measured over time and what would lead to a change.

For any new trial headline, find the comparison group and the length of follow-up. Check whether the participants had the same major conditions that you do. Then look for the analysis used and the reasons people stopped treatment. This takes longer than reading the headline, but it gives the number a meaning you can use.

As of October 1, 2026, retatrutide remains investigational. The FDA states that it is not a component of an approved drug and cannot be used in compounding under federal law. The agency also warns about products sold to consumers under misleading research-use labels. The clinical results discussed here do not verify the identity or quality of a vial sold online. FDA's current guidance

TRIUMPH-1 makes the case for retatrutide much stronger. The dose comparisons show why future care will need to track tolerability alongside weight loss. Strength, nutritional intake, and physical function also deserve attention when the amount of weight lost is this large.

Reply with the weight-loss treatment comparison you want me to explain next.

For entertainment and education only. Not medical advice. Talk to your doctor before starting anything.